RxDoctor Payments DataLook up a doctor →

Justin Moon

Neurology · Denver, CONPI 1215019609

Payments from drug & device makers

$1,394,614in general payments, 2019–2025

Across 4,378 payments — averaging $318.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$408K
  • Lilly USA, LLC$231K
  • Amgen$183K
  • Eisai Inc.$169K
  • Teva Pharmaceuticals USA, Inc.$64K
  • Averitas Pharma Inc.$60K
  • plus $278K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)890$408,021
Lilly USA, LLC457$230,727
Amgen(2 entities)248$182,749
Eisai Inc.251$169,088
Teva Pharmaceuticals USA, Inc.193$63,694
Averitas Pharma Inc.157$60,430
GRT US Holding, Inc.144$53,685
Biohaven Pharmaceuticals, Inc.86$51,014
Axsome Therapeutics, Inc.54$37,447
Pfizer185$26,039
Biohaven Pharmaceutical Holding Company Ltd.53$22,743
Lundbeck LLC106$18,944
Biogen117$14,939
Eli Lilly23$12,037
CSL Behring39$6,365
Ipsen Biopharmaceuticals, Inc24$5,335
UCB, Inc.115$3,116
Novartis145$2,055
AstraZeneca(2 entities)61$1,846
EMD Serono, Inc.68$1,671
Livanova USA, Inc.30$1,553
Biodelivery Sciences International, Inc.1$1,500
Bristol Myers Squibb63$1,454
SK Life Science, Inc.59$1,246
Banner Life Sciences, LLC18$1,183
Genentech USA, Inc.53$1,076
MDD US Operations, LLC35$974
Merz Pharmaceuticals, LLC55$963
Sanofi39$887
Neurocrine Biosciences, Inc.43$827
TG Therapeutics, Inc.32$716
Neurelis, Inc.24$638
Argenx US, Inc.24$592
Impel Pharmaceuticals Inc.17$573
Jazz Pharmaceuticals Inc.25$548
Acadia Pharmaceuticals Inc29$469
Sunovion Pharmaceuticals Inc.31$405
Adamas Pharmaceuticals, Inc.22$370
Grifols USA, LLC15$363
Catalyst Pharmaceuticals, Inc.20$346
Scilex Pharmaceuticals Inc.21$335
Akcea Therapeutics, Inc.14$334
Tanabe Pharma America, Inc.18$321
Supernus Pharmaceuticals, Inc.29$309
Zyla Life Sciences, Inc.31$302
Abbott10$263
Assertio Therapeutics, Inc.13$198
Mallinckrodt Enterprises LLC16$196
Merz North America, Inc.10$191
Upsher-smith Laboratories LLC8$169
Acorda Therapeutics, Inc7$164
Tonix Medicines, Inc.6$162
Amneal Pharmaceuticals LLC8$148
Octapharma USA, Inc.6$137
Life Molecular Imaging Ltd9$131
Zap Surgical Systems, Inc.1$126
Avid Radiopharmaceuticals, Inc.1$125
Novo Nordisk1$125
Bausch Health US, LLC6$122
Johnson & Johnson(2 entities)7$121

How this compares

$1,394,614 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$435,313
Medicare patients
485
Services billed
36,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →